Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma

JAMA Oncol. 2019 Nov 1;5(11):1631-1633. doi: 10.1001/jamaoncol.2019.3158.


This cohort study examines whether PBRM1 alterations are associated with response to immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.